Safety of treatments for inflammatory bowel disease : Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved..
Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn's disease and ulcerative colitis is unknown, due to the current knowledge regarding their pathogenesis, effective treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs. These observations prompted the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) to establish Italian guidelines on the safety of currently available treatments for Crohn's disease and ulcerative colitis. These guidelines discuss the use of aminosalicylates, systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNFα antagonists, vedolizumab, and combination therapies. These guidelines are based on current knowledge derived from evidence-based medicine coupled with clinical experience of a national working group.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 49(2017), 4 vom: 27. Apr., Seite 338-358 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Biancone, Livia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.10.2017 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dld.2017.01.141 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM268659184 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM268659184 | ||
| 003 | DE-627 | ||
| 005 | 20231224223042.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dld.2017.01.141 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0895.xml |
| 035 | |a (DE-627)NLM268659184 | ||
| 035 | |a (NLM)28161290 | ||
| 035 | |a (PII)S1590-8658(17)30145-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Biancone, Livia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of treatments for inflammatory bowel disease |b Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.10.2017 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a growing incidence and prevalence in several countries, including Italy. Although the etiology of Crohn's disease and ulcerative colitis is unknown, due to the current knowledge regarding their pathogenesis, effective treatment strategies have been developed. Several guidelines are available regarding the efficacy and safety of available drug treatments for inflammatory bowel diseases. Nevertheless, national guidelines provide additional information adapted to local feasibility, costs and legal issues related to the use of the same drugs. These observations prompted the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) to establish Italian guidelines on the safety of currently available treatments for Crohn's disease and ulcerative colitis. These guidelines discuss the use of aminosalicylates, systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNFα antagonists, vedolizumab, and combination therapies. These guidelines are based on current knowledge derived from evidence-based medicine coupled with clinical experience of a national working group | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Medical treatments | |
| 650 | 4 | |a Safety | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Aminosalicylic Acid |2 NLM | |
| 650 | 7 | |a 5B2658E0N2 |2 NLM | |
| 650 | 7 | |a Cyclosporine |2 NLM | |
| 650 | 7 | |a 83HN0GTJ6D |2 NLM | |
| 650 | 7 | |a vedolizumab |2 NLM | |
| 650 | 7 | |a 9RV78Q2002 |2 NLM | |
| 650 | 7 | |a Mercaptopurine |2 NLM | |
| 650 | 7 | |a E7WED276I5 |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Annese, Vito |e verfasserin |4 aut | |
| 700 | 1 | |a Ardizzone, Sandro |e verfasserin |4 aut | |
| 700 | 1 | |a Armuzzi, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrese, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Caprioli, Flavio |e verfasserin |4 aut | |
| 700 | 1 | |a Castiglione, Fabiana |e verfasserin |4 aut | |
| 700 | 1 | |a Comberlato, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Cottone, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Danese, Silvio |e verfasserin |4 aut | |
| 700 | 1 | |a Daperno, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a D'Incà, Renata |e verfasserin |4 aut | |
| 700 | 1 | |a Frieri, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Fries, Walter |e verfasserin |4 aut | |
| 700 | 1 | |a Gionchetti, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Kohn, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Latella, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Milla, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Orlando, Ambrogio |e verfasserin |4 aut | |
| 700 | 1 | |a Papi, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Petruzziello, Carmelina |e verfasserin |4 aut | |
| 700 | 1 | |a Riegler, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzello, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Saibeni, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Scribano, Maria Lia |e verfasserin |4 aut | |
| 700 | 1 | |a Vecchi, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Vernia, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Meucci, Gianmichele |e verfasserin |4 aut | |
| 700 | 0 | |a Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) |e verfasserin |4 aut | |
| 700 | 1 | |a Aratari, Annalisa |e investigator |4 oth | |
| 700 | 1 | |a Bossa, Fabrizio |e investigator |4 oth | |
| 700 | 1 | |a Cappello, Maria |e investigator |4 oth | |
| 700 | 1 | |a Cassinotti, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Chiriatti, Alberto |e investigator |4 oth | |
| 700 | 1 | |a Fiorino, Gionata |e investigator |4 oth | |
| 700 | 1 | |a Formica, Vincenzo |e investigator |4 oth | |
| 700 | 1 | |a Guidi, Luisa |e investigator |4 oth | |
| 700 | 1 | |a Losco, Alessandra |e investigator |4 oth | |
| 700 | 1 | |a Mocciaro, Filippo |e investigator |4 oth | |
| 700 | 1 | |a Onali, Sara |e investigator |4 oth | |
| 700 | 1 | |a Pastorelli, Luca |e investigator |4 oth | |
| 700 | 1 | |a Pica, Roberta |e investigator |4 oth | |
| 700 | 1 | |a Principi, Mariabeatrice |e investigator |4 oth | |
| 700 | 1 | |a Renna, Sara |e investigator |4 oth | |
| 700 | 1 | |a Ricci, Chiara |e investigator |4 oth | |
| 700 | 1 | |a Rispo, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Rogai, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Sarmati, Loredana |e investigator |4 oth | |
| 700 | 1 | |a Scaldaferri, Franco |e investigator |4 oth | |
| 700 | 1 | |a Spina, Luisa |e investigator |4 oth | |
| 700 | 1 | |a Tambasco, Rosy |e investigator |4 oth | |
| 700 | 1 | |a Testa, Anna |e investigator |4 oth | |
| 700 | 1 | |a Viscido, Angelo |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver |d 2000 |g 49(2017), 4 vom: 27. Apr., Seite 338-358 |w (DE-627)NLM108968790 |x 1878-3562 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2017 |g number:4 |g day:27 |g month:04 |g pages:338-358 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dld.2017.01.141 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2017 |e 4 |b 27 |c 04 |h 338-358 | ||